![GLP-2 [T] (60mg)](https://static.wixstatic.com/media/4ca31e_f0ac9079b7054ed68d485f88899cec6a~mv2.png/v1/fill/w_655,h_752,al_c,q_90,enc_avif,quality_auto/4ca31e_f0ac9079b7054ed68d485f88899cec6a~mv2.png)
GLP-2 [T] (60mg)
Tirzepatide is a highly effective, once-weekly injectable peptide developed by Eli Lilly that transformed the landscape of metabolic medicine. It is a dual GIP and GLP-1 receptor agonist, making it the first approved drug to target two distinct metabolic gut hormones simultaneously.
It is commercially sold under two different brand names depending on its medical use:
Mounjaro: FDA-approved for the treatment of Type 2 Diabetes.
Zepbound: FDA-approved for Chronic Weight Management (obesity or overweight with atしくは weight-related comorbidities) and Obstructive Sleep Apnea.
The Dual-Agonist Mechanism
First-generation weight loss medications like semaglutide (Ozempic/Wegovy) only mimic one hormone: GLP-1. Tirzepatide’s breakthrough comes from its "twin-cretin" approach, combining GLP-1 with a second hormone called GIP.
GLP-1 (Glucagon-like peptide-1): Delays stomach emptying (keeping you physically full longer), acts on the brain to suppress appetite, and prompts the pancreas to release insulin when blood sugar levels rise.
GIP (Glucose-dependent insulinotropic polypeptide): Works in tandem with GLP-1 to maximize insulin secretion and curb nausea. Crucially, GIP receptors are abundant in fat tissue, where they help optimize lipid (fat) metabolism and improve how your body stores and breaks down energy.
Clinical Trial Results
In Eli Lilly’s hallmark SURMOUNT and SURPASS clinical trials, tirzepatide demonstrated unprecedented efficacy, significantly outperforming single-agonist GLP-1 therapies.
Clinical Target | Average Trial Outcomes (At Highest 15 mg Dose) |
Weight Reduction | Patients without diabetes achieved an average of 20.9% to 22.5% body weight loss over 72 weeks (roughly 52 lbs). |
A1C Reduction | Patients with Type 2 Diabetes saw blood sugar control drop by an average of 2.0 to 2.4 percentage points, with many achieving complete remission. |
Cardiovascular Health | Showed marked improvements in lowering blood pressure, reducing systemic inflammation, and cutting fasting triglycerides. |
Side Effects & Contemporary Market Status
Like all medications in this class, the most frequent side effects are gastrointestinal, including nausea, diarrhea, vomiting, and constipation. These are usually mild-to-moderate and occur most frequently when increasing doses.
Key Updates & Insurance Milestones
Sleep Apnea Approval: The FDA expanded tirzepatide's approval to include treating moderate-to-severe obstructive sleep apnea in patients with obesity, as it significantly reduces airway blockages during sleep.
Major Insurance Expansion: Coverage has expanded dramatically across major commercial insurance frameworks. Additionally, the launch of targeted bridge initiatives has made the drug far more accessible out-of-pocket for eligible Medicare Part D recipients.
The Compounding Crackdown: Because brand-name supply shortages have begun resolving due to ramped-up manufacturing, federal health agencies have severely tightened regulations around unauthorized, compounded "copycat" versions from bulk chemical suppliers.
){kind=link}